EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

First‐Line Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective, Multicenter, Real‐World Study

Alizée Simon iD, Cyril Abdeddaim, DucTrung Nguyen, Patrice Gallet, Didier Peiffert, Aurélien Lambert, Lionnel Geoffrois

Head & Neck · 2025

DOI: 10.1002/hed.28211 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Head & Neck, 2025. Verfasst von Alizée Simon und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Institut de Cancérologie de Lorraine, Nancy, France. Hauptthemen laut MEDLINE: Squamous Cell Carcinoma of Head and Neck, Neoplasm Recurrence, Local, Antibodies, Monoclonal, Humanized, Head and Neck Neoplasms. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In Europe, pembrolizumab with or without chemotherapy is the recommended first‐line treatment for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC), with a combined positive score (CPS) ≥ 1. In France, the TPExtreme (TPEx) regimen is preferred for CPS < 1. These regimens were studied in selected populations, which may not reflect real‐world patients.

Methods

We reviewed all R/M HNSCC cases treated with first‐line regimens between January 2021 and December 2023 in Nancy and Lille. Data on patient history, treatments, survival, response, and safety were collected. PFS and OS were analyzed using the Cox multivariable regression model, adjusting for the covariates age, Eastern Cooperative Oncology Group (ECOG) performance status, comorbidities, and nutritional status.

Results

The analysis included 290 patients; 19% received pembrolizumab alone, 28% received pembrolizumab with chemotherapy, 19% received TPEx, and 20% received adapted regimens. PFS and OS differed significantly between groups. Median PFS and OS were respectively 2.9 and 9.4 months for pembrolizumab, 6 and 15.5 months for pembrolizumab‐chemotherapy, 5.9 and 13.7 months for TPEx, and 4.3 and 10 months for adapted regimens. Pembrolizumab alone is the safest regimen.

Conclusion

This retrospective study reflects real‐world first‐line therapy for R/M HNSCC in two French cancer institutes. Pembrolizumab combined with chemotherapy is the preferred treatment option.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Squamous Cell Carcinoma of Head and NeckNeoplasm Recurrence, LocalAntibodies, Monoclonal, HumanizedHead and Neck NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsAntineoplastic Agents, ImmunologicalHumansRetrospective StudiesMaleFemaleMiddle AgedAgedFranceAdultAged, 80 and overNeoplasm Metastasis

Stichwörter der Autor:innen

R/M HNSCCfirst‐linehead and neck cancerimmunotherapyreal‐world

Substanzen

pembrolizumabAntibodies, Monoclonal, HumanizedAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Medical Oncology, Institut de Cancérologie de Lorraine, Nancy, France.
  • Faculté de médecine de Nancy, Université de Lorraine, Nancy, France.
  • Department of Medical Oncology, Centre Oscar Lambret, Lille, France.
  • Department of ENT - Head and Neck Surgery, Centre Hospitalier Regional Universitaire de Nancy, Nancy, France.
  • Department of Radiation Oncology, Institut de Cancérologie de Lorraine, Nancy, France.

ORCID-Profile: Alizée Simon

Zitieren

APA

Simon, A., Abdeddaim, C., Nguyen, D., Gallet, P., Peiffert, D., Lambert, A., & Geoffrois, L. (2025). First‐Line Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective, Multicenter, Real‐World Study. Head & Neck. https://doi.org/10.1002/hed.28211

Vancouver

Simon A, Abdeddaim C, Nguyen D, Gallet P, Peiffert D, Lambert A, et al. First‐Line Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective, Multicenter, Real‐World Study. Head & Neck. 2025. doi:10.1002/hed.28211

BibTeX
@article{Simon2025,
  author = {Simon, Alizée and Abdeddaim, Cyril and Nguyen, DucTrung and Gallet, Patrice and Peiffert, Didier and Lambert, Aurélien and Geoffrois, Lionnel},
  title = {First‐Line Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective, Multicenter, Real‐World Study},
  journal = {Head & Neck},
  year = {2025},
  doi = {10.1002/hed.28211}
}
Kostenlos starten →